Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And DetractorsSeeking Alpha • Wednesday
Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesotheliomaGlobeNewsWire • Wednesday
Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratoriesGlobeNewsWire • Tuesday
Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung CancerBusiness Wire • 10/25/26
Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancerGlobeNewsWire • 10/25/26
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)Business Wire • 10/23/26
Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)GlobeNewsWire • 10/23/26
Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesZacks Investment Research • 10/22/26
Roche, In A Buy Zone, Matches Revenue Forecasts Despite Light Pharma SalesInvestors Business Daily • 10/22/26
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]GlobeNewsWire • 10/22/26
Genentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage PortfolioBusiness Wire • 10/19/26
Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolioGlobeNewsWire • 10/19/26
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthZacks Investment Research • 10/16/26
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)Business Wire • 10/16/26
FDA approves Roche's Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)GlobeNewsWire • 10/16/26